SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
Category · MitochondriaMech 8/10
View ProductAll pathwaysEmerging Limited Strong
Cellular energy & mitochondrial systems
Mitochondrial Optimization Research Pathway
Energy. Efficiency. Cellular signal.
This pathway explores peptides studied for mitochondrial efficiency, oxidative stress modulation, ATP production, and cellular energy signaling.
System Overview
The biological system this pathway studies.
Mitochondria generate ATP through oxidative phosphorylation across the electron transport chain (ETC), while also regulating reactive oxygen species, calcium handling, and apoptotic signaling. Cardiolipin — a phospholipid concentrated in the inner mitochondrial membrane — stabilizes ETC complexes and shapes membrane potential. Research in this domain studies how peptide compounds interact with mitochondrial membranes, energy yield, and cellular stress responses.
Educational research context · not medical advice
Why This Pathway Matters
Mitochondria are the cellular engines that generate ATP and regulate oxidative balance.
Researchers study this pathway to understand how peptides interact with the inner mitochondrial membrane, electron transport chain efficiency, and reactive oxygen species. Mitochondrial signaling shapes cellular energy availability, metabolic flexibility, and resilience under stress.
ATP production
Electron transport chain efficiency and energy yield.
Oxidative stress
Reactive oxygen species balance and cardiolipin stability.
Cellular energy signaling
AMPK, metabolic flexibility, and mitochondrial biogenesis.
Educational research context · not medical advice
Research Progression Model
3 biological phases · click to explore
1
Research Phase 1
Mitochondrial Protection
Research focus
SS-31 is studied for its interaction with cardiolipin inside the inner mitochondrial membrane. Research explores its role in mitochondrial stability, oxidative stress reduction, and electron transport chain support.
2
Research Phase 2
Cellular Energy Signaling
Research focus
MOTS-c is a mitochondrial-derived peptide studied for AMPK signaling, metabolic flexibility, insulin sensitivity pathways, and cellular energy regulation.
3
Research Phase 3
Systemic Metabolic Support
Research focus
These compounds are studied in metabolic and body composition research, especially in relation to fat metabolism, growth hormone signaling, and visceral adiposity research.
Studied Compounds
AOD-9604
Low / mixed for human outcomesSits within lipid metabolism and adrenergic signaling pathways at the adipocyte level in preclinical models.
Preclinical studies often used short windows (e.g. 14 days in obese mice)Tesamorelin
Strong within approved contextOperates within the GH/IGF-1 axis at the hypothalamic-pituitary signaling layer, upstream of systemic IGF-1 effects.
Clinical studies measured visceral adipose tissue changes at 26 weeks, with extension data to 52 weeksMechanism Flow
How signaling unfolds across the three research phases.
Phase 1 covers the initial biological process. Phase 2 maps the signaling cascades downstream. Phase 3 describes systemic effects studied in research models.
1
Phase 1 · Membrane-level protection
- Interaction with cardiolipin in the inner mitochondrial membrane
- Studied for ETC complex stability and membrane potential preservation
- Reported reductions in oxidative stress markers in preclinical models
2
Phase 2 · Cellular signaling
- AMPK activation and nutrient-sensing pathways
- Insulin-sensitivity and glucose handling research
- Mitochondrial-to-nucleus retrograde signaling models
3
Phase 3 · Systemic metabolic effects
- Body composition and visceral adiposity research
- Lipid metabolism and fat oxidation pathways
- Growth hormone axis interactions explored in adjacent literature
Studied Compounds
Compounds studied within this pathway.
Each entry summarizes the mechanism explored in research literature. Not a recommendation, dosing guide, or protocol.
- SS-31ElamipretideModerate
Binds cardiolipin in the inner mitochondrial membrane; studied for stabilizing electron transport chain integrity.
- MOTS-cEmerging
Studied for AMPK activation, metabolic flexibility, and insulin sensitivity pathways.
- AOD-9604Low
Studied for lipolytic signaling without GH-like growth effects.
- TesamorelinStrong
Studied for GHRH receptor activation and pulsatile GH release.
Research Observation Timeline Across This Pathway
Timeline patterns measured in studies of these compounds.
Every compound in this pathway has a primary study window described in the research literature. Windows below describe research observation periods only — not expected personal outcomes.
Moderate disease-specific clinical evidence · 1Emerging preclinical · 1Low / mixed for human outcomes · 1Strong within approved context · 1
- SS-31Moderate disease-specific clinical evidence
Measured in studies: Weeks to months in human disease-context trials
Endpoint type · Biomarker, functional, and imaging endpoints
- MOTS-cEmerging preclinical
Measured in studies: Days to weeks in preclinical metabolic studies
Endpoint type · Biomarker and metabolic signaling endpoints
- AOD-9604Low / mixed for human outcomes
Measured in studies: Preclinical studies often used short windows (e.g. 14 days in obese mice)
Endpoint type · Biomarker and adipose tissue endpoints
- TesamorelinStrong within approved context
Measured in studies: Clinical studies measured visceral adipose tissue changes at 26 weeks, with extension data to 52 weeks
Endpoint type · Imaging and biomarker endpoints
These windows reflect research observation periods only, not guaranteed personal outcomes.
Research Insights
What current research focuses on.
- Most ETC and cardiolipin-targeted research draws from preclinical and early clinical work in mitochondrial disease models.
- MOTS-c and other mitochondrial-derived peptides remain primarily in animal and in-vitro literature.
- Mechanism-of-action studies are stronger than long-term outcome data.
Research Limitations
Where the evidence base is incomplete.
- Human trial data is limited and mostly confined to specific disease populations.
- Long-term safety profiles for chronic mitochondrial-targeted peptides are not established.
- Translation from cellular models to whole-organism effects remains an open research question.
Transparency note · evidence gaps disclosed for research integrity
Research Relationship Overview
How these compounds are studied together.
Each phase groups compounds with mechanistic overlap. The diagram shows which compounds are explored in combination within published research literature — not a recommended use strategy.
Pathway hubResearch phaseStudied compoundMechanistic overlap
DisclaimerThis visualization reflects research relationships and does not represent a recommended use strategy. Compounds shown here are studied together in research contexts only — this is not a protocol, dosing guide, or medical advice.
Catalog · Research compounds
Related Compounds Available
Compounds referenced in this pathway's research literature. Each links to its full Library profile — mechanism, evidence, and research context. Research use only.
Moderate
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Category · MitochondriaMech 7/10
View ProductAOD-9604
Fragment of hGH (176-191) studied in lipid metabolism research.
Category · Fat LossMech 5/10
View ProductTesamorelin
GHRH analog studied for visceral adiposity research.
Category · Growth Hormone AxisMech 9/10
View ProductFor research use only · Not for human consumption
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.